ABBOTT PARK, Ill., Jan. 15, 2015
/PRNewswire/ -- Abbott (NYSE: ABT) announced today the results of
the tender offer and related consent solicitation commenced by its
wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation
("ALH"), to purchase for cash any and all of the outstanding 5.125%
Senior Notes due 2022 (the "Notes") issued by CFR International
SpA, a Chilean corporation and subsidiary of ALH. The tender offer
and related consent solicitation expired at 12 p.m., New York
City time, on Jan. 14, 2015.
Abbott has been advised that an aggregate of $294,093,000 principal amount of Notes,
representing 98% of the outstanding Notes, was tendered, including
the $292,893,000 principal amount of
Notes that was previously tendered and purchased. ALH has accepted
for payment all Notes that were validly tendered and not
subsequently withdrawn or previously purchased.
About Abbott
Abbott is a global healthcare company devoted to improving life
through the development of products and technologies that span the
breadth of healthcare. With a portfolio of leading, science-based
offerings in diagnostics, medical devices, nutritionals and branded
generic pharmaceuticals, Abbott serves people in more than 150
countries and employs approximately 69,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at
@AbbottNews.
Private Securities Litigation Reform Act of 1995 – A Caution
Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995. Abbott cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those indicated in the
forward-looking statements. Economic, competitive, governmental,
technological and other factors that may affect Abbott's operations
are discussed in Item 1A, "Risk Factors," to our Annual Report
on Securities and Exchange Commission Form 10-K for the year
ended Dec. 31, 2013, and are incorporated by reference. Abbott
undertakes no obligation to release publicly any revisions to
forward-looking statements as a result of subsequent events or
developments, except as required by law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abbott-announces-results-of-tender-offer-and-consent-solicitation-for-cfr-international-spa-5125-senior-notes-due-2022-300020845.html
SOURCE Abbott